Intraperitoneal cancer-immune microenvironment promotes peritoneal dissemination of gastric cancer.
Gastric cancer
peritoneal dissemination
tumor microenvironment
tumor-associated macrophages
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
14
06
2019
revised:
12
09
2019
accepted:
18
09
2019
entrez:
20
11
2019
pubmed:
20
11
2019
medline:
20
11
2019
Statut:
epublish
Résumé
A solid tumor consists of cancer and stromal cells, which comprise the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are usually abundant in the TME, contributing to tumor progression. In cases of peritoneal dissemination of gastric cancer (GC), the contribution of intraperitoneal TAMs remains unclear. Macrophages from peritoneal washings of GC patients were analyzed, and the link between intraperitoneal TAMs and GC cells was investigated to clarify the interaction between them in peritoneal dissemination. Macrophages were predominant among leukocytes constituting the microenvironment of the peritoneal cavity. The proportion of CD163-positive TAMs was significantly higher in stage IV than in stage I GC. Co-culture with TAMs potentiated migration and invasion of GC. IL-6 was the most increased in the medium of in vitro co-culture of macrophages and GC, and IL-6 elevation was also observed in the peritoneal washes with peritoneal dissemination. An elevated concentration of intraperitoneal IL-6 was correlated with a poor prognosis in clinical cases. In conclusion, intraperitoneal TAMs are involved in promoting peritoneal dissemination of GC via secreted IL-6. TAM-derived IL-6 could be a potential therapeutic target for peritoneal dissemination of GC.
Identifiants
pubmed: 31741772
doi: 10.1080/2162402X.2019.1671760
pii: 1671760
pmc: PMC6844331
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e1671760Informations de copyright
© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
J Immunol Res. 2016;2016:9720912
pubmed: 27975071
Int J Cancer. 2013 May 1;132(9):1977-85
pubmed: 23034889
Gastric Cancer. 2015 Oct;18(4):740-50
pubmed: 25231913
Nat Immunol. 2016 Mar;17(3):215-6
pubmed: 26882248
Ann Transl Med. 2016 Nov;4(21):438
pubmed: 27942529
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Invest. 2016 Oct 3;126(10):3672-3679
pubmed: 27482883
J Clin Invest. 2009 Oct;119(10):3172-81
pubmed: 19729837
Nature. 2014 Sep 25;513(7519):559-63
pubmed: 25043024
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Br J Surg. 2003 Sep;90(9):1113-9
pubmed: 12945079
Int J Cancer. 1980 Aug;26(2):171-6
pubmed: 6970727
J Int Med Res. 2003 Mar-Apr;31(2):69-75
pubmed: 12760309
Br J Cancer. 2009 Jan 13;100(1):134-44
pubmed: 19088723
World J Gastroenterol. 2016 Aug 14;22(30):6829-40
pubmed: 27570420
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Trends Immunol. 2012 Nov;33(11):571-7
pubmed: 22883707
Cancer Res. 2007 Mar 15;67(6):2649-56
pubmed: 17363585
Br J Surg. 2000 Feb;87(2):236-42
pubmed: 10671934
Cancer Lett. 2016 May 28;375(1):51-61
pubmed: 26945971
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
Int Immunopharmacol. 2014 Nov;23(1):37-45
pubmed: 25130606
Clin Cancer Res. 2000 Jul;6(7):2702-6
pubmed: 10914713
Ann Surg Oncol. 2005 May;12(5):347-53
pubmed: 15915368
Cancer Cell. 2009 Feb 3;15(2):103-13
pubmed: 19185845
Cancer Sci. 2018 Oct;109(10):3263-3271
pubmed: 30076658
Cancer Res. 1992 Jun 15;52(12):3317-22
pubmed: 1596890
Oncotarget. 2016 Dec 6;7(49):80521-80542
pubmed: 27602954
J Surg Oncol. 2016 Jan;113(1):29-35
pubmed: 26603684
J Clin Invest. 2014 Apr;124(4):1853-67
pubmed: 24642471
Clin Dev Immunol. 2012;2012:948098
pubmed: 22778768
Oncotarget. 2017 Mar 28;8(13):20741-20750
pubmed: 28186964
Gastric Cancer. 2016 Oct;19(4):1052-1065
pubmed: 26621525
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Food Funct. 2013 Feb;4(2):266-76
pubmed: 23135314
Gut. 2015 Apr;64(4):627-35
pubmed: 24870621
Mol Cancer Res. 2011 Dec;9(12):1658-67
pubmed: 21976712
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
PLoS One. 2012;7(12):e50946
pubmed: 23284651
Cancer Immunol Immunother. 1990;31(1):49-52
pubmed: 2407352
Oncotarget. 2015 Apr 30;6(12):10592-603
pubmed: 25871392
Gastric Cancer. 2012 Sep;15 Suppl 1:S27-37
pubmed: 21809111
Oncol Lett. 2016 May;11(5):3403-3408
pubmed: 27123124
Atherosclerosis. 2012 Mar;221(1):2-11
pubmed: 21978918
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
J Immunol. 1989 Aug 15;143(4):1206-9
pubmed: 2787359
Biochim Biophys Acta. 2009 Nov;1793(11):1623-33
pubmed: 19665497
Cancer Lett. 2015 Jan 28;356(2 Pt B):321-31
pubmed: 25281477
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
BMC Cancer. 2012 Jul 23;12:306
pubmed: 22824040
Trends Mol Med. 2018 May;24(5):472-489
pubmed: 29655673
Nat Med. 2006 Oct;12(10):1213-9
pubmed: 17013385
Gastroenterology. 2014 Dec;147(6):1393-404
pubmed: 25181692
Int J Cancer. 2015 Sep 1;137(5):1035-46
pubmed: 25604508
J Exp Clin Cancer Res. 2018 Dec 11;37(1):307
pubmed: 30537992
Cancer Cell. 2013 Aug 12;24(2):257-71
pubmed: 23948300
Dig Dis Sci. 2016 Jun;61(6):1561-71
pubmed: 26738736
J Cell Physiol. 2013 Jul;228(7):1404-12
pubmed: 23065796
Clin Cancer Res. 2008 Jan 15;14(2):428-34
pubmed: 18198221